BioRestorative Therapies, Inc. ("BRT"), develops products and medical therapies using cell and tissue protocols, primarily involving adult stem cells, including:
• brtxDISC™ (Disc Implanted Stem Cells), BRT’s lead therapeutic product, is a mesenchymal stem cell product derived from autologous human bone marrow. It is to be used in an investigational non-surgical treatment for protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease and is intended for patients who have failed non-invasive procedures and potentially face the prospect of surgery. The treatment, utilizing brtxDISC™, involves culturing a patient’s own stem cells and then delivering them to the damaged disc in an outpatient procedure.
• ThermoStem® is a treatment using brown fat stem cells that is under development for metabolic disorders including diabetes and obesity. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels.
The Company’s common stock trades under the stock symbol “BRTX” and is listed on the OTCBB exchange.
As of December 31, 2014, there were 33,923,179 shares of the issuer's common stock outstanding.
The Company’s common stock can be purchased or sold through any registered broker or through an online trading account.
The Company does not offer a direct share purchase plan at this time.
The Company does not issue dividends or have a DRIP program at this time.
Company’s press releases, annual reports, quarterly reports and other materials can be accessed through our website under Investor Relations.
The transfer agent for the common stock is: Island Stock Transfer (www.islandstocktransfer.com)
SEC documents can be accessed through our website under SEC Filings or at http://www.sec.gov/cgi-bin/browse-edgar?company=biorestorative+therapies&match=contains&action=getcompany
BioRestorative Therapies’ fiscal year end is December 31.